FENC
Fennec Pharmaceuticals Inc.
Biotechnology
Market Cap$194M
5Y Perf.-6.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
FENC vs HALO vs JAZZ vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.55B
5Y Perf.+164.2%
JAZZ
Jazz Pharmaceuticals plc
Biotechnology
Market Cap$14.17B
5Y Perf.+89.2%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
FENC vs HALO vs JAZZ vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FENC | HALO | JAZZ | RARE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $194M | $7.55B | $14.17B | $2.57B |
| Revenue (TTM) | $39M | $1.40B | $4.44B | $669M |
| Net Income (TTM) | $-7M | $317M | $29M | $-609M |
| Gross Margin | 93.1% | 81.9% | 66.9% | 83.6% |
| Operating Margin | -12.0% | 58.4% | 13.9% | -83.9% |
| Forward P/E | 54.3x | 8.0x | 9.1x | — |
| Total Debt | $19M | $0.00 | $5.42B | $1.28B |
| Cash & Equiv. | $27M | $134M | $1.39B | $434M |
FENC vs HALO vs JAZZ vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FENC
HALO
JAZZ
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fennec Pharmaceutic… (FENC) | 100 | 93.6 | -6.4% |
| Halozyme Therapeuti… (HALO) | 100 | 264.2 | +164.2% |
| Jazz Pharmaceutical… (JAZZ) | 100 | 189.2 | +89.2% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FENC vs HALO vs JAZZ vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Fennec Pharmaceuticals Inc. is the stronger pick specifically for growth and revenue expansion. JAZZ also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
FENC
Fennec Pharmaceuticals Inc.
The Growth Play
FENC is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 123.7%, EPS growth 97.3%
- 123.7% revenue growth vs JAZZ's 4.9%
Best for: growth exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.51
- 5.6% 10Y total return vs JAZZ's 52.9%
- Lower volatility, beta 0.51, current ratio 4.66x
- Beta 0.51, current ratio 4.66x
Best for: income & stability and long-term compounding
JAZZ
Jazz Pharmaceuticals plc
The Momentum Pick
JAZZ is the clearest fit if your priority is momentum.
- +129.4% vs RARE's -27.4%
Best for: momentum
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FENC | 123.7% revenue growth vs JAZZ's 4.9% |
| Value | HALO | Better valuation composite |
| Quality / Margins | HALO | 22.7% margin vs RARE's -91.0% |
| Stability / Safety | HALO | Beta 0.51 vs FENC's 1.78 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | JAZZ | +129.4% vs RARE's -27.4% |
| Efficiency (ROA) | HALO | 12.5% ROA vs RARE's -45.8%, ROIC 73.4% vs -89.4% |
FENC vs HALO vs JAZZ vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2020
FY 2025
FY 2025
FY 2025
FENC vs HALO vs JAZZ vs RARE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGRARE
Who Leads Where
HALO leads in 3 of 6 categories
FENC leads 0 • JAZZ leads 0 • RARE leads 0 • 2 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
JAZZJazz Pharmaceuticals …
0leads
FENCFennec Pharmaceutical…
0leads
HALOHalozyme Therapeutics…
3leads
6 Total Categories
CATEGORYLEADERvs FENCvs JAZZMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
HALO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JAZZ is the larger business by revenue, generating $4.4B annually — 114.4x FENC's $39M. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to RARE's -91.0%. On growth, FENC holds the edge at +78.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FENCFennec Pharmaceut… | HALOHalozyme Therapeu… | JAZZJazz Pharmaceutic… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $39M | $1.4B | $4.4B | $669M |
| EBITDAEarnings before interest/tax | -$5M | $945M | $994M | -$536M |
| Net IncomeAfter-tax profit | -$7M | $317M | $29M | -$609M |
| Free Cash FlowCash after capex | -$8M | $645M | $1.2B | -$487M |
| Gross MarginGross profit ÷ Revenue | +93.1% | +81.9% | +66.9% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -12.0% | +58.4% | +13.9% | -83.9% |
| Net MarginNet income ÷ Revenue | -17.9% | +22.7% | +0.7% | -91.0% |
| FCF MarginFCF ÷ Revenue | -20.6% | +46.2% | +28.1% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +78.7% | +51.6% | +19.1% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.1% | -2.1% | +3.9% | -17.2% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — FENC and HALO and JAZZ each lead in 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, HALO's 8.2x EV/EBITDA is more attractive than FENC's 55.6x.
| Metric | FENCFennec Pharmaceut… | HALOHalozyme Therapeu… | JAZZJazz Pharmaceutic… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Market CapShares × price | $194M | $7.6B | $14.2B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $187M | $7.4B | $18.2B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -433.13x | 25.05x | -38.66x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 54.27x | 7.96x | 9.07x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 1.09x | — | — |
| EV / EBITDAEnterprise value multiple | 55.57x | 8.20x | 23.74x | — |
| Price / SalesMarket cap ÷ Revenue | 4.09x | 5.41x | 3.32x | 3.82x |
| Price / BookPrice ÷ Book value/share | — | 162.76x | 3.19x | — |
| Price / FCFMarket cap ÷ FCF | 7.21x | 11.72x | 10.92x | — |
Evenly matched — FENC and HALO and JAZZ each lead in 2 of 6 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), FENC scores 6/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | FENCFennec Pharmaceut… | HALOHalozyme Therapeu… | JAZZJazz Pharmaceutic… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +6.5% | +0.7% | -6.1% |
| ROA (TTM)Return on assets | -15.0% | +12.5% | +0.3% | -45.8% |
| ROICReturn on invested capital | — | +73.4% | +2.1% | -89.4% |
| ROCEReturn on capital employed | +9.0% | +38.2% | +2.2% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 5 | 4 |
| Debt / EquityFinancial leverage | — | — | 1.26x | — |
| Net DebtTotal debt minus cash | -$7M | -$134M | $4.0B | $842M |
| Cash & Equiv.Liquid assets | $27M | $134M | $1.4B | $434M |
| Total DebtShort + long-term debt | $19M | $0 | $5.4B | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -1.57x | 46.08x | -3.72x | -14.49x |
HALO leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
HALO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HALO five years ago would be worth $13,909 today (with dividends reinvested), compared to $2,391 for RARE. Over the past 12 months, JAZZ leads with a +129.4% total return vs RARE's -27.4%. The 3-year compound annual growth rate (CAGR) favors HALO at 28.4% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | FENCFennec Pharmaceut… | HALOHalozyme Therapeu… | JAZZJazz Pharmaceutic… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.8% | -8.8% | +30.4% | +10.7% |
| 1-Year ReturnPast 12 months | +11.6% | -5.3% | +129.4% | -27.4% |
| 3-Year ReturnCumulative with dividends | -12.8% | +111.8% | +62.8% | -44.5% |
| 5-Year ReturnCumulative with dividends | +15.9% | +39.1% | +28.2% | -76.1% |
| 10-Year ReturnCumulative with dividends | -42.3% | +559.7% | +52.9% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -4.5% | +28.4% | +17.6% | -17.8% |
HALO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — HALO and JAZZ each lead in 1 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than FENC's 1.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JAZZ currently trades 98.0% from its 52-week high vs RARE's 61.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FENCFennec Pharmaceut… | HALOHalozyme Therapeu… | JAZZJazz Pharmaceutic… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 0.51x | 0.68x | 1.36x |
| 52-Week HighHighest price in past year | $9.92 | $82.22 | $230.40 | $42.37 |
| 52-Week LowLowest price in past year | $5.65 | $47.50 | $97.50 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +69.9% | +78.0% | +98.0% | +61.6% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 47.7 | 74.7 | 67.7 |
| Avg Volume (50D)Average daily shares traded | 177K | 1.4M | 843K | 1.8M |
Evenly matched — HALO and JAZZ each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: FENC as "Buy", HALO as "Buy", JAZZ as "Buy", RARE as "Buy". Consensus price targets imply 159.7% upside for FENC (target: $18) vs -0.0% for JAZZ (target: $226).
| Metric | FENCFennec Pharmaceut… | HALOHalozyme Therapeu… | JAZZJazz Pharmaceutic… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $75.60 | $225.75 | $48.36 |
| # AnalystsCovering analysts | 7 | 27 | 48 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | +4.5% | +0.9% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 3 of 6 categories
Loading custom metrics...
FENC vs HALO vs JAZZ vs RARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FENC or HALO or JAZZ or RARE a better buy right now?
For growth investors, Fennec Pharmaceuticals Inc.
(FENC) is the stronger pick with 123. 7% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 0x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate Fennec Pharmaceuticals Inc. (FENC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FENC or HALO or JAZZ or RARE?
On forward P/E, Halozyme Therapeutics, Inc.
is actually cheaper at 8. 0x.
03Which is the better long-term investment — FENC or HALO or JAZZ or RARE?
Over the past 5 years, Halozyme Therapeutics, Inc.
(HALO) delivered a total return of +39. 1%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: HALO returned +559. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FENC or HALO or JAZZ or RARE?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 51β versus Fennec Pharmaceuticals Inc. 's 1. 78β — meaning FENC is approximately 247% more volatile than HALO relative to the S&P 500.
05Which is growing faster — FENC or HALO or JAZZ or RARE?
By revenue growth (latest reported year), Fennec Pharmaceuticals Inc.
(FENC) is pulling ahead at 123. 7% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: Fennec Pharmaceuticals Inc. grew EPS 97. 3% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FENC or HALO or JAZZ or RARE?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — FENC leads at 93. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FENC or HALO or JAZZ or RARE more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 0x forward P/E versus 54. 3x for Fennec Pharmaceuticals Inc. — 46. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FENC: 159. 7% to $18. 00.
08Which pays a better dividend — FENC or HALO or JAZZ or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is FENC or HALO or JAZZ or RARE better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Fennec Pharmaceuticals Inc. (FENC) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +559. 7%, FENC: -42. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FENC and HALO and JAZZ and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: FENC is a small-cap high-growth stock; HALO is a small-cap high-growth stock; JAZZ is a mid-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(FENC: 78.7% · HALO: 51.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.